UCB has been granted a patent for thiophene derivatives, which are compounds designed to treat or prevent disorders linked to IgE, including allergies, type 1 hypersensitivity, and familial sinus inflammation. The patent covers both the compounds and their pharmaceutically acceptable salts. GlobalData’s report on UCB gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on UCB, Human telomerase RT biomarker was a key innovation area identified from patents. UCB's grant share as of June 2024 was 49%. Grant share is based on the ratio of number of grants to total number of patents.
The patent US12018021B2 encompasses a series of claims related to novel compounds characterized by specific chemical structures, particularly those containing a cyclopropanecarbonylamino moiety. The primary claim outlines a compound of formula (I) or its pharmaceutically acceptable salts, which can be further specified by various substituents and structural modifications. Subsequent claims detail specific variations of these compounds, including those with distinct functional groups such as sulfonyl, carbamoyl, and various alkyl or aryl substituents. The claims also explore the potential for these compounds to exist in different stereoisomeric forms, indicating a focus on the pharmacological implications of stereochemistry in drug design.
Additionally, the patent includes claims for pharmaceutical compositions that incorporate these compounds, suggesting their potential therapeutic applications. The extensive list of specific compounds and their derivatives indicates a broad scope of potential uses, particularly in the field of medicinal chemistry. The claims highlight the versatility of the compounds, which may be tailored for various biological activities, thus positioning them as candidates for further research and development in pharmaceutical applications. Overall, the patent presents a comprehensive framework for the exploration of these compounds in therapeutic contexts, emphasizing their structural diversity and potential efficacy.
To know more about GlobalData’s detailed insights on UCB, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
